Latest news with #NationalBiotechnologyStrategy
Mid East Info
4 days ago
- Business
- Mid East Info
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region - Middle East Business News and Information
As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Business Upturn
4 days ago
- Business
- Business Upturn
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) — As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at [email protected]. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
4 days ago
- Business
- Yahoo
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
KFSHRC accounts for 52.4% of all active clinical trials in Saudi Arabia. RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) -- As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ A photo accompanying this announcement is available at
Yahoo
13-05-2025
- Business
- Yahoo
Saudi Arabia Healthcare Bioconvergence Market Research Report 2025, Competitive Analysis of Saudi Biotechnology Manufacturing, Lifera Omics, Amgen, Tamer Group, and Merck
The Saudi Arabia Healthcare Bioconvergence Market, valued at USD 550.33 Million in 2024, is projected to reach USD 1.14 Billion by 2030, growing at a CAGR of 4.42%. Technological innovations, including AI and robotics, along with increased R&D investments, fuel market expansion, supporting personalized medicine and enhanced patient care. Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Healthcare Bioconvergence Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to Saudi Arabia Healthcare Bioconvergence Market is poised for remarkable growth, projected to increase from USD 550.33 million in 2024 to USD 1.14 billion by 2030, at a CAGR of 4.42% This growth is driven by the integration of technologies such as AI, machine learning, and big data analytics with biotechnology, transforming medical diagnostics, personalized treatments, and disease management. The utilization of AI-powered systems for analyzing genetic data and clinical trials is enabling healthcare providers to develop more precise, data-driven treatment plans, enhancing patient care and surgical outcomes through innovations in robotic surgeries and smart healthcare investments in research and development, along with collaborations with international tech firms, are fueling the advancement of bioconvergence technologies. These efforts are leading to the creation of next-generation medical devices and therapies combining biotechnology with state-of-the-art Forces The heightened demand for innovative healthcare solutions is a major driver of market growth. The National Biotechnology Strategy aims to position Saudi Arabia as a leading regional and global biotechnology hub, with a focus on self-sufficiency in vaccines, biomanufacturing, and genomics. These initiatives align with Vision 2030, promoting the modernization of healthcare infrastructure and boosting the demand for bioconvergence medicine is gaining significant traction, where treatment plans are tailored to individual patient characteristics. Bioconvergence plays a pivotal role by integrating genetic data and clinical insights to deliver customized healthcare solutions. This approach enhances treatment precision and effectiveness, driving the market Advancements Advancements in AI and data analytics are transforming diagnostic capabilities in Saudi Arabia, improving patient monitoring and healthcare decision-making. The integration of telemedicine, digital health records, and robotic surgery is setting new healthcare benchmarks, enhancing patient outcomes, and optimizing healthcare management. AI algorithms provide fast and accurate diagnoses, particularly benefiting complex conditions like cancer and cardiovascular diseases, bolstering the demand for bioconvergence rise of robotics and minimally invasive surgery is further propelling the market, with Saudi Arabia accounting for 60% of healthcare expenditure within the GCC. Government efforts, including a USD 50.4 billion allocation to healthcare, emphasize the sector's importance and support the growth of bioconvergence Challenges and Trends High initial investment costs pose a challenge, requiring sophisticated infrastructure and substantial R&D expenditure. However, the integration of blockchain for data security offers a compelling trend, addressing data breaches and improving interoperability across platforms, crucial for efficient healthcare and Segmental Insights The Northern and Central regions, particularly Riyadh, dominate the market due to government healthcare investments and the presence of key healthcare institutions. The fast-growing drug discovery segment benefits from AI and machine learning, enhancing the development of effective therapies and augmenting market Market Players Saudi Biotechnology Manufacturing Co Lifera Omics Amgen Saudi Arabia Limited Tamer Group Merck KGaA Key Topics Covered: 1. Product Overview1.1. Market Definition1.2. Scope of the Market 2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology 3. Executive Summary3.1. Overview of the Market 4. Saudi Arabia Healthcare Bioconvergence Market Outlook4.1. Market Size & Forecast4.2. Market Share & Forecast4.3. Market Map 5. Eastern Healthcare Bioconvergence Market Outlook5.1. Market Size & Forecast5.2. Market Share & Forecast 6. Western Healthcare Bioconvergence Market Outlook6.1. Market Size & Forecast6.2. Market Share & Forecast 7. Northern & Central Healthcare Bioconvergence Market Outlook7.1. Market Size & Forecast7.2. Market Share & Forecast 8. Southern Healthcare Bioconvergence Market Outlook8.1. Market Size & Forecast8.2. Market Share & Forecast 9. Market Dynamics9.1. Drivers9.2. Challenges 10. Market Trends & Developments 11. Policy & Regulatory Landscape 12. Saudi Arabia Economic Profile 13. Competitive Landscape Saudi Biotechnology Manufacturing Co Lifera Omics Amgen Saudi Arabia Limited Tamer Group Merck KGaA For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Arab News
05-05-2025
- Business
- Arab News
Biotech program to empower Saudi innovators
RIYADH: The Ministry of Health has launched a biotechnology accelerator program to empower Saudi innovators in biotechnology and life sciences. The initiative aims to enhance their scientific and commercial readiness, attract investment, and expand their global market reach, the Saudi Press Agency reported. It also seeks to boost their contributions to healthcare quality, aligning with the National Biotechnology Strategy and the Health Sector Transformation Program under Vision 2030, which envisions a thriving, innovation-driven economy and a vibrant society with sustainable health and quality of life. The seven-month program offers participants mentorship, capacity development, and networking opportunities with local and international investors and experts. It includes workshops, seminars, individual consultations, and a chance to present innovations at the BIO 2025 Conference. The application deadline is May 8. Interviews and initial selection will take place from May 15-20, with final acceptances announced on May 25. The ministry continues to advance health innovation and accelerate the progress of promising national projects. It encourages all Saudi innovators, entrepreneurs, and startups to register for the program and inquire via [email protected]
